Provided by Tiger Fintech (Singapore) Pte. Ltd.

LUCID DIAGNOSTICS INC.

1.29
0.0000
Volume:640.57K
Turnover:823.55K
Market Cap:139.57M
PE:-1.03
High:1.34
Open:1.31
Low:1.26
Close:1.29
Loading ...

Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology

PR Newswire
·
27 Mar

Lucid Diagnostics Price Target Maintained With a $2.00/Share by Cantor Fitzgerald

Dow Jones
·
26 Mar

PAVmed Inc (PAVM) Q4 2024 Earnings Call Highlights: Strategic Growth and Financial Stability

GuruFocus.com
·
26 Mar

Lucid Diagnostics: Strong Growth Potential Driven by Strategic Advancements and Market Expansion

TIPRANKS
·
25 Mar

Lucid Diagnostics Inc : Btig Cuts Target Price to $2 From $2.5

THOMSON REUTERS
·
25 Mar

Lucid Diagnostics Reports Strong Growth and Future Plans

TIPRANKS
·
25 Mar

Lucid Diagnostics Is Maintained at Buy by Needham

Dow Jones
·
25 Mar

Lucid Diagnostics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
24 Mar

Lucid Diagnostics Inc. (LUCD) Reports Q4 Loss, Lags Revenue Estimates

Zacks
·
24 Mar

Lucid Diagnostics Q4 2024 GAAP EPS $(0.19), Inline, Sales $1.20M Miss $1.42M Estimate

Benzinga
·
24 Mar

Lucid Diagnostics Inc: Qtrly Loss per Share $0.20

THOMSON REUTERS
·
24 Mar

Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

THOMSON REUTERS
·
24 Mar

Press Release: Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Dow Jones
·
24 Mar

Lucid Diagnostics Inc expected to post a loss of 19 cents a share - Earnings Preview

Reuters
·
21 Mar

Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (Nccn) Guidelines NOW Include Esophageal Precancer Screening

THOMSON REUTERS
·
20 Mar

Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening

PR Newswire
·
20 Mar

Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

PR Newswire
·
18 Mar

BTIG Keeps Their Buy Rating on Lucid Diagnostics (LUCD)

TIPRANKS
·
18 Mar

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025

PR Newswire
·
10 Mar

BRIEF-Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering

Reuters
·
06 Mar